MedTrace Logo

Analgesic Efficacy of Ultrasound Guided Erector Spinae Block for Modified Radical Mastectomy

NCT04732364 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-02-01

No results posted yet for this study

Summary

To compare the analgesic efficacy of dexmedetomidine and magnesium sulphate as adjuvants to levobupivacaine in erector spinae plane block in modified radical mastectomy surgery for acute and chronic pain management.

Conditions

  • Pain, Postoperative

Interventions

PROCEDURE

ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy

Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle

PROCEDURE

ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy

Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle

PROCEDURE

ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy

Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle

Sponsors & Collaborators

  • South Egypt Cancer Institute

    lead OTHER

Principal Investigators

  • peter R Edward, MSc · specialist

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-30
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04732364 on ClinicalTrials.gov